Peptide record

TPDB91954

pVEC Antibacterial Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Toxicity Tumor-homing Peptides modified_plain modified
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91954
pVEC
Antibacterial Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Toxicity Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP i2APP B3Pred BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP TumorHoPe2.0
modified_plain
Yes
A 18-aa modified multi-activity (Antibacterial, Antifungal, Antiparasitic, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
LLIILRRRIRKQAHAHSK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
18 reviewed residue count
Amidation Activity
L Activity
Amphipathic Cationic and amphipathic Activity
Linear Tetramer Activity
Free Activity
N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O Activity
Evidence Records 4 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

HeLa, CHO and Jurkat cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Amphipathic
Protein derived
Fluorophore [5(6)-carboxyfluorescein]
Cytoplasm
Clathrin mediated endocytosis
In vitro
CCSSCGGGHHHHSCCC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

E. Coli K12 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Protein derived
Membrane damage
In vitro and in vivo
CCSSCGGGHHHHSCCC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Assay & Model

ICR-CD-1 mice
ICR-CD-1 mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic and amphipathic
Protein derived
Radio-Iodine labelled
Endocytosis and direct penetration
In vivo
CCCSCCSSTTSCSSSSSCCTTTTTCSSCC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

Sk-Br-3, Jimt-1, A431, Jurkat-Cells

Assay & Model

Athymic BALB/c nude mice xenografted A431tumors
Athymic BALB/c nude mice xenografted A431tumors

Source & Reference

CPPsite3.0
CPPsite3
EP2928502B1

Other

Natural residues Tetramer L Amphipathic
Protein derived
Anti-EGFR mAb matuzumab (Mat)
Lower internalization efficiency with values of 25% or less
Endocytosis
In vitro and in vivo
CCCCCCCCCCCCC
Additional Detail Fields 1 fields
CCSSCGGGHHHHSCCC CCCSCCSSTTSCSSSSSCCTTTTTCSSCC CCCCCCCCCCCCC